List view / Grid view



Biosimilars create opportunities for sustainable cancer care

22 February 2017 | By Professor Josep Tabernero, Chair of the ESMO Cancer Medicines Working Group

Dr Josep Tabernero explains the benefits of biosimilars, showing how they can create sustainable, safe and affordable access to medicine globally...

Drawing the boundaries of data disclosure in clinical trials

22 February 2017 | By ,

In the context of clinical trial data disclosure, since 2010 the regulatory impetus has shifted towards enhanced disclosure obligations, culminating in the publication of a ‘pro-active’ policy on the publication of clinical trial data for medicinal products for human use1 (Policy 0070) by the European Medicines Agency (EMA) in October…

Driving business value from pharmaceutical serialisation

15 February 2017 | By Nicolás Giménez Stamminger, Manager IT Advisory, KPMG Switzerland

KMPG’s Nicolás Giménez Stamminger explains why serialisation is the solution to counterfeit medicines and how to implement a cost-effective serialisation strategy…

2017 pipelines: AstraZeneca – another challenging year

8 February 2017 | By Brian White and Paul Taylor, Healthcare Analysts, Cantor Fitzgerald Europe

Healthcare analysts predict another difficult year ahead for the pharmaceutical giant, after 2016 was beset with competitive and pricing pressures...

Transforming healthcare in the era of Trump: An opportunity to disrupt

20 January 2017 | By Stephen Klasko, President and CEO, Thomas Jefferson University and Jefferson Health; Editor-in-Chief, Healthcare Transformation

With Trump’s rule imminent, President and CEO of Thomas Jefferson University, Stephen Klasko, puts forth a manifesto for healthcare reform, disruption and change…

Send this to a friend